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Tumor-associated macrophages (TAMs) can be educated within the tumor microenvironment to promote
cancer development and progression. While TAM-targeted agents have largely focused on macrophage
depletion as an anticancer strategy, it is becoming increasingly evident that TAM re-education may rep-
resent a more effective approach. In this perspective, we discuss different means to achieve TAM re-
education, and review the beneficial effects of these strategies, particularly when combined with immune
checkpoint inhibitors.
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Tumor-associated macrophages in the cancer microenvironment
Tumors develop and progress within a complex tissue environment involving a multitude of intercellular inter-
actions, not only between heterogeneous cancer cells, but also with the many normal cell types that collectively
comprise the tumor microenvironment (TME). The TME can be defined as the numerous innate and adaptive
immune cell types, stromal cells, extracellular matrix, blood and lymphatic vessel networks that comprise the tumor
mass along with the cancer cells. Normal cells in the TME are educated and can consequently be co-opted during
the process of tumor progression to actively promote malignancy [1–3]. Although the precise composition of the
TME varies in an organ-dependent manner, tumor-associated macrophages (TAMs) have emerged as one of the
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Figure 1. Macrophage targeting strategies in cancer. The plasticity of macrophages and their high capacity to adapt to external signals
allow cancer cells to hijack their biological functions. In the majority of solid tumors, macrophages recruited to the tumor niche are
educated to acquire protumoral phenotypes. Several strategies have been developed to target macrophages in the tumor
microenvironment, including their killing or re-education. Most macrophage-targeted therapies are currently focused on CSF-1R
inhibitors, which either deplete or reprogram macrophages. Macrophages can also be targeted via a CD40 agonist that boosts the
antitumoral response. Another approach is via disruption of macrophage-derived PD-1 and its interactions with PD-L1 on other cell types.
CCL5-CCR5 blockade can result in the re-education of macrophages and subsequent tumor regression. Reprogramming of macrophages
can also be achieved by either pharmacologic inhibition or genetic deletion of PI3Kgamma, Tie2, DICER or histone deacetylase class IIa, or
via antibody-based targeting of the macrophage-derived protein MARCO.
most numerous and critical cell types across the majority of cancers analyzed, with potent multifaceted roles in
regulating cancer progression and modulating the response to therapeutic intervention (Figure 1).
An early clue as to the importance of TAMs in the TME came from analyses of patient samples, in which high
numbers of TAMs correlated with poor prognosis for the majority of cancers examined [4]. Several subsequent meta-
analyses, with cumulative numbers in the thousands [5,6], have borne out these early findings to confirm that TAM
abundance is associated with worse patient prognosis in the vast majority of solid tumors, with colorectal cancer
representing one consistent exception to this correlation. However, the simple presence of macrophages per se in the
TME does not necessarily indicate a tumor-promoting microenvironment. Instead, it is the precise phenotype of
the macrophage, which results from both its ontogeny and tumor-mediated education, that determines its functions
and consequently how one would aim to therapeutically target these tumor-associated cells (Table 1 & Table 2).
Macrophages are central guardians of the body that continuously patrol and monitor their surroundings in order
to detect perturbations to the homeostatic state, such as infection and cell death. When abnormalities are detected,
macrophages quickly adapt to changes in the surrounding microenvironment [7]. Through a wide variety of intra-
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Table 1. Monotherapies used to re-educate tumor-associated macrophages.
Molecular target Therapeutic agent Study (year)
CSF-1/CSF-1R Small molecule inhibitor: BLZ945 Pyonteck et al. (2013); Quail et al. (2016)
Small molecule inhibitor: PLX3397 Cuccarese et al. (2017); Yan et al. (2017); Zhu et al. (2014)
Small molecule inhibitor: PLX6134 Perry et al. (2018)
Anti-CSF-1 antibody Zhu et al. (2014)
Anti-CSF-1R antibody Hoves et al. (2018); Wiehagen et al. (2017)
CCL5-CCR5 Small molecule inhibitor: Maraviroc Halama et al. (2016)
CD40 Monoclonal agonist antibody Beatty et al. (2011); Beatty et al. (2013); Hoves et al.
(2018); Perry et al. (2018); Wiehagen et al. (2017)
PD-1/PD-L1 PD-L1 genetic deletion Gordon et al. (2017)
Anti-PD-1 antibody
Anti-human PD-L1 small protein HAC
DICER Genetic deletion Baer et al. (2016)
IL-12 Viral delivery Saha et al. (2017)
HDAC TMP195 Guerriero et al. (2017)
PI3K Small molecule inhibitor: TG100-115 Kaneda et al. (2016)
Genetic deletion
Small molecule inhibitor: IPI-549 De Henau et al. (2016); Kaneda et al. (2016)
MARCO Anti-MARCO antibody Georgoudaki et al. (2016)
TIE2 Small molecule inhibitor: rebastinib Harney et al. (2017)
Table 2. Studies incorporating the re-education of tumor-associated macrophages to enhance the efficacy of other
therapeutic interventions.
Molecular target Combination treatment Study (year)
CSF-1/CSF-1R Anti-PD-1, anti-CTLA-4 antibody, gemcitabine Zhu et al. (2014)
BKM120, FK506, AS1517499, OSI906 Quail et al. (2016)
Dovitinib, Vatalanib Yan et al. (2017)
PD-1/PD-L1 Anti-CD47 antibody Gordon et al. (2017)
CD40 CSF-1/CSF-1R blockade Hoves et al. (2018); Perry et al. (2018); Wiehagen et al.
(2017)
DICER Anti-CD40, anti-PD-1 antibody Baer et al. (2016)
HDAC Carboplatin, paclitaxel Guerriero et al. (2017)
Anti-PD-1
PI3K Anti-PD-1 antibody De Henau et al. (2016); Kaneda et al. (2016)
Anti-CTLA4 antibody De Henau et al. (2016)
MARCO Anti-CTLA4 antibody Georgoudaki et al. (2016)
TIE2 Paclitaxel, eribulin Harney et al. (2017)
and extracellular receptors, macrophages respond to a diverse set of stimuli ranging from small molecules such as
metabolites, tomolecules of intermediate complexity such as cytokines and chemokines, to a family of heterogeneous
signaling molecules that are connected with pathogen and danger associated patterns (PAMPs and DAMPs) [8].
Under the influence of these external stimuli, macrophages can oscillate between different activation profiles.
Two extreme poles of macrophage activation have been described in detail, originally based on in vitro studies
of macrophage biology: pro-inflammatory, classically activated M1 and anti-inflammatory, alternatively activated
M2 macrophages. The former produce type I pro-inflammatory cytokines, participate in antigen presentation and
have been ascribed antitumorigenic activity, while the latter produce type II cytokines, promote anti-inflammatory
responses and have protumorigenic functions [7,8]. As these two activation programs of macrophages have opposite
effects and have been proposed to be mutually exclusive, their activation status is often referred as ‘polarization’
toward one or the other extreme.
However, in vivo studies, particularly in the context of cancer, reveal a far more complex landscape than
represented by this simple binary classification. The TME is sculpted during its evolution by multiple cell types,
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including cancer cells, which secrete factors that attract and subsequently educate macrophages [9]. The plasticity
of macrophages and their high capacity to adapt to external signals allow their biological functions to be hijacked
and manipulated in cancer [9,10]. Thus, it is now well established that in the majority of solid tumors, macrophages
acquire protumoral phenotypes following their recruitment to the tumor niche. Transcriptional profiling of bulk
TAMs revealed enrichment in certain M2-like genes, indicating a partial ‘alternatively activated’ macrophage
phenotype [11–14]. Considerable emphasis to date has been placed on defining TAMs in this simple ‘either/ or’
M1 or M2 state, often to the exclusion of other hypotheses. Indeed, a recent study, taking advantage of single-cell
RNA sequencing in breast cancer patient samples, reported expression of both M1 and M2 genes in the same cells,
with similar findings reported in gliomas [15,16]. Thus, a comprehensive and integrated approach in which TAMs
are rather analyzed based on their ontogeny, TME-mediated education, phenotypic diversity, location within the
TME and their resulting tumor-modulating functions, is critical to undertake.
Strategies to deplete or re-educate TAMs
The high abundance of TAMs within tumors, their genomic stability and rapid response to external stimuli
together highlight their potential as a therapeutic target in cancer [17]. The most widely used strategy to date
has been via TAM depletion from the tumor mass, through different methods including inhibition of colony
stimulating factor-1/colony stimulating factor-1 receptor (CSF-1/CSF-1R) [18,19], CCL2/CCR2 inhibition [20]
and delivery of clodronate liposomes [21]. Despite promising results in numerous preclinical animal models of solid
tumors, ongoing clinical trials employing the therapeutic strategy of TAM depletion have brought modest or no
clinical benefits for cancer patients to date [17,18,22,23]. Moreover, cessation of macrophage/ monocyte depletion
was shown to actually accelerate tumor growth in a breast cancer metastasis mouse model [24], suggesting possible
post-treatment complications and emphasizing the necessity for a much closer evaluation of this approach in
preclinical and clinical settings.
Interestingly, several conventional anticancer treatments have been shown to affectmacrophage phenotypes [17,25].
Multiple studies have reported the dual nature of the macrophage response to chemotherapy. For example, in both
patient-derived xenografts [26] and syngeneic mouse models of breast carcinoma [27,28], paclitaxel treatment induces
a recruitment of macrophages to the tumor. In the PyMT-TS1 breast cancer model, TAMs were shown to protect
tumor cells from the toxic effects of paclitaxel and other chemotherapies, through non cell-autonomous regulation
of mitotic arrest [29] and via the secretion of cathepsin proteases [28]. Newly arrived TAMs, particularly Tie2+
perivascular macrophages, can in turn help tumor cells to disseminate [26] and form metastases. On the other
hand, there is also evidence that paclitaxel can repolarize macrophages through TLR4 signaling toward a more
pro-inflammatory phenotype [30], which controls the response of melanomas to paclitaxel. Thus, chemotherapy
can either induce TAM re-education or enhance their tumor-promoting functions. Similar divergent results were
reported for the effects of radiotherapy on TAM biology [17,31]. The effect of irradiation on TAM biology depends
on the type, dose and localization of irradiation [31]. Thus, more tailored approaches to interfere with TAM biology
may represent a better approach to achieve efficient macrophage re-education, such as antibody-based targeting
of the macrophage-derived protein MARCO [32] and other molecularly restricted strategies which are described in
detail below.
An antitumoral strategy that has proven successful in mouse glioma models relied on macrophage-tailored re-
education rather than their depletion [33,34]. Administration of two independent, chemically distinct small molecule
inhibitors of CSF-1R (BLZ945, PLX3397) resulted in macrophage depletion from healthy tissues including the
brain, as expected. Surprisingly, TAMs were not depleted within the glioma microenvironment, but were rather
protected from cell death by glioma-supplied cytokines including GM-CSF and IFN-γ, and persisted in the face of
CSF-1R inhibition [33,34]. In-depth analysis of these surviving TAMs revealed changes in their transcription profile
with a reprogramming into a less protumoral phenotype in association with significantly augmented phagocytic
capacities. This led to rapid tumor regression in a 7-day preclinical trial [33,34], suggesting that TAM-centered
re-education might be most efficient as an antitumor therapeutic strategy [1,35]. In addition, the PLX3397-based
re-education of TAMs in vivo rendered glioma cells sensitive to different tyrosine kinase inhibitors (TKIs), leading
to tumor regression [34]. In combination trials performed for just one week, more than half of the tumors showed
>30% regression in volume, while in the PLX3397 monotherapy arm approximately 3% of the tumors reached
this level of regression, with most tumors showing a growth stabilization, and none of the tumors treated with the
other TKIs alone regressed [34].
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Here, we discuss recent research that extends this concept beyond gliomas and demonstrates the feasibility
of TAM re-education in the TME across diverse cancer types and its beneficial effect on tumor regression and
enhancing response to other agents in combination trials (Table 1 & Table 2). The persistence of macrophages
in gliomas treated with CSF-1R inhibitors was an unexpected finding [33], nonetheless, similar observations have
subsequently been reported for other tumor types. In a pancreatic ductal adenocarcinoma (PDAC) mouse model,
therapeutic use of the CSF-1R inhibitor PLX3397 decreased total TAM numbers, yet a subset of macrophages
persisted [36]. These remaining TAMs showed a distinct transcriptional profile to PDAC-associated macrophages
in steady state, with higher expression of genes involved in antitumor immunity and antigen presentation, among
others. Similarly, treatment with a neutralizing antibody against the CSF-1 ligand resulted in a selective decrease
in protumoral CD206+ TAMs in the PDAC model, thereby skewing the immunosuppressive microenvironment,
as CD206- TAMs persisted [36]. Thus, in both of these representative examples, while the strategy of CSF-1/
CSF-1R inhibition led to a partial depletion of TAMs, the reprogramming of the subset of TAMs which survived
had important effects on the pancreatic TME. Moreover, overall changes in the TAM compartment induced by
CSF-1/CSF-1R blockade significantly enhanced the response to immune checkpoint inhibitors (programmed cell
death protein 1 [PD-1] and cytotoxic T-lymphocyte-associated protein 4 [CTLA-4] antagonists) combined with
chemotherapy [36], revealing the further potential of TAM-targeted therapies when administered in multitargeted
approaches. Interestingly, in an implantable mouse model of lung adenocarcinoma deficient for KRAS and p53,
PLX3397 treatment resulted in a tumor volume that was approximately tenfold lower when compared with control
animals, without decreasing overall TAM density [37]. Instead, the spatial distribution of TAMs was altered within
the treated tumors when compared with untreated controls. These results suggest that the lung adenocarcinoma
TME, similarly to glioma [33,34], specifically protected TAMs from PLX3397-mediated cell death within the tumor
niche [37].
Importantly, recent findings have shown that the efficacy of CSF-1/CSF-1R blockade can be blunted by
dynamic adaptive changes within the TME. In gliomas, where macrophages can comprise up to 30% of total
tumor mass [33,38–40], CSF-1R-targeted therapies were proven successful in short-term preclinical trials resulting in
substantial tumor regression [33,34]. In long-term preclinical trials, while the initial tumor regression was striking
and completely penetrant, with prolonged treatment approximately half of the high-grade tumors ultimately
recurred [41]. Interestingly, this acquired resistance was a result of dynamic alterations within the brain TME that
adapted over time to overcome CSF-1R targeting. Critically, combining CSF-1R blockade with inhibition of any
of the factors identified to mediate the recurrence, including IGF-1, PI3K or NFAT, resulted in circumvention of
the resistance mechanisms and glioma eradication. Notably, inhibition of any of these factors as a monotherapy
did not induce the regression of gliomas, highlighting the dynamic acquisition of new mechanisms of resistance –
and consequently the exposure of further vulnerabilities over time in the TME of treated tumors.
Another mechanism of resistance to CSF-1R inhibition, accounting for the modest antitumor efficacy of CSF-
1R blockade in diverse models of melanoma, breast, colon and lung tumors, was shown to be mediated by
certain cancer-associated fibroblasts that can express CSF-1R [42]. Upon CSF-1R inhibition, the cancer-associated
fibroblasts underwent a switch in cytokine production and recruited granulocytic cells to the tumor [42]. As a
consequence, only simultaneous targeting of granulocytic cells and macrophages led to decreased tumor growth.
In another preclinical study, CSF-1R inhibition was found to actually promote LLC lung cancer metastasis as a
consequence of the loss of myeloid cell-supplied IL-15, which is also a survival factor for NK cells [43]. The indirect
depletion of NK cells impaired clearance of LLC cells in the circulation, and specifically increased metastatic seeding
– though had no effect on established metastases. By exogenously supplying IL-15 in conjunction with CSF-1R
inhibition, the authors could restore NK cells and thereby diminish metastasis [43]. Together, these highlighted
examples indicate that macrophage targeting may represent a more effective therapeutic strategy when used in
combination with other immune/stromal cell-targeted approaches to overcome adaptive or intrinsic resistance
mechanisms.
The CSF-1R inhibitor, PLX3397, has been tested in an escalating dose Phase I clinical trial followed by a
Phase II extension study in patients with advanced giant cell synovial tumors that overexpress CSF-1. Results from
these studies indicated that PLX3397 was well tolerated and in the extension study, 52% of patients experienced
an antitumor response after treatment. In a Phase II study in patients with recurrent glioblastoma (following the
standard of care therapy), treatment with PLX3397 was well tolerated, but did not improve progression-free survival
compared with those in the radiotherapy and temozolomide group [44]. Another CSF-1R inhibitor, BLZ945, is
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currently under assessment in a trial in advanced-stage solid tumors either as a single agent or in combination with
the anti-PD-1 antibody (NCT02829723).
In addition to CSF-1/CSF-1R inhibitors, a number of other strategies have been found to result in TAM
re-education. For example, a CD40 agonist was reported as a potent agent to repolarize macrophages and boost
antitumoral immune responses in a PDACmousemodel [45]. Administration of the CD40 agonist induced secretion
of the chemokine CCL2 by tumor tissue and from circulating monocytes and resulted in monocyte/macrophage
accumulation in the PDAC lesion [46]. This therapeutic intervention also elevated systemic production of IFN-
γ, which polarized circulating monocytes prior to their arrival at the tumor site. Importantly, the beneficial
effect of this treatment was abolished when CCL2 or Ly6C-expressing monocytes/macrophages were depleted [46].
Thus, in this PDACmodel, monocytes were first activated/polarized by therapy-induced systemic changes toward a
proinflammatory phenotype, and then subsequently recruited to the tumor site where they drove fibrotic degradation
and a decrease in collagen within the TME. The remodeling of extracellular matrix in PDACs led to partial tumor
stabilization and sensitization of these tumors to gemcitabine [46]. CD40 agonists are now being explored clinically
as a therapeutic approach in diverse solid tumors [47]. For example, the agonistic anti-CD40 antibody CP-870,893
was tested in an escalating Phase I study and has been well tolerated, resulting in antitumor activity [48]. RO7009789,
another CD40 agonist, is currently being investigated in four combinatorial clinical trials in advanced-stage solid
tumors (NCT02760797), (NCT02304393), (NCT02665416), (NCT025843).
Interestingly, several studies found that the combination of different CD40 agonists with CSF-1/CSF-1R path-
way inhibition amplified antitumoral effects and resulted in a more potent tumor regression than treatment with
single agents [49–51]. In three complementary studies which investigated a broad spectrum of tumors including ge-
netically engineered melanoma [50], implantable solid tumor models of colon adenocarcinoma and carcinoma [49,51],
breast adenocarcinoma and sarcoma [49], combination treatments resulted in an amplification of changes in the
TAM compartment composition. Immunosuppressive M2-like TAMs were depleted while the remaining TAMs
were induced to secrete proinflammatory cytokines, including TNF-α, and expressed higher levels of NOS2, thereby
rendering tumors susceptible to T-cell-mediated attack. Moreover, CD40-CSF-1R combinatorial targeting had a
synergistic effect with anti-PDL1 treatment and led to a complete response in 90% of tumors in a preclinical study
of colon adenocarcinoma [52].
Indeed, a recent study showed that repolarization of TAMs can also be achieved by disruption of macrophage-
derived PD-1 and external PD-L1 interactions [53]. In colon carcinoma models, PD-1 was expressed not only on T
cells, but also on a subset of TAMs that accumulated with tumor progression over time in the TME. These cells were
characterized by low MHC II levels, and high expression of CD206 and CD11c, in line with M2-like polarization.
PD-1/PD-L1 blockade led to TAM re-education as evidenced by increased phagocytosis. The combined treatment
resulted in a significant reduction in tumor growth in both immunocompetent and immunocompromised (NSG
and Rag2/Il2rγ-/-) animals [53]. As the latter lack a functional adaptive immune system, the antitumoral effect of
the treatment was largely mediated by macrophages. Indeed, if TAMs were first depleted by a CSF-1R blocking
antibody before the combination treatment was initiated, the beneficial effects of PD-L1 neutralization were lost.
Of note, the depletion of macrophages also led to a slower tumor growth when compared with untreated controls at
the same time points. Finally, when PD-1/PD-L1 blockade was combined with an anti-CD47 antibody, preventing
its interaction with SIRPα- which inhibits the recognition and phagocytosis of tumor cells by macrophages, an
additive effect of the therapies was observed.
Reprogramming of macrophages has also been shown by either pharmacologic inhibition or genetic deletion
of the γ isoform of phosphoinositide 3-kinase (PI3Kgamma) [54]. The ablation of PI3Kγ resulted in suppression
of tumor growth in several cancer models, including lung, breast and head and neck squamous cell carcinoma.
Detailed analysis revealed that the treatment led to a switch in TAM phenotype with induced expression of MHC
II, while the total numbers of TAMs in the TME remained similar to control tumors. Repolarization of TAMs
together with a higher abundance of proinflammatory cytokines in the TME resulted in immune system activation
and slower tumor growth. Importantly in a lung carcinomamodel, both the re-education of macrophages and TAM
depletion, either by a CSF-1R-targeting antibody or clodronate liposomes, had a similar inhibitory effect on tumor
growth as PI3Kγ inhibition, but no additive effect of two strategies when combined was observed. In addition,
PI3Kγ inhibition sensitized tumors to immune checkpoint inhibitors [54,55], again showing the importance of
macrophage-mediated priming of the TME for optimal immunotherapy efficacy (Table 2).
Another promising strategy for targeting macrophages via Tie2 TKIs was demonstrated during metastatic
dissemination. In the ‘tumor microenvironment of metastasis (TMEM)’ that occurs within the primary tumor in
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close proximity to the blood vessels, Tie2hi macrophages were shown to accumulate and induce local disruption of
vascular junctions, transient vascular permeability, and tumor cell intravasation [56]. In a subsequent study using
a MMTV-PyMT orthotopic model, the Tie2 inhibitor rebastinib significantly reduced the growth of implanted
mammary carcinomas by 75%, and when combined with paclitaxel resulted in an additional reduction in tumor
growth by 90% [57]. Similarly, rebastinib alone reduced the formation of lung metastasis by 72%, and by 93% in
combination with paclitaxel. Rebastinib also significantly inhibited liver metastasis by 75% compared with controls
in the RIP1-Tag2 pancreatic neuroendocrine tumor model [57]. Examination of the effects of rebastinib at the
cellular level demonstrated a reduction in Tie2 myeloid cell infiltration, anti-angiogenic effects, and blockade of
tumor cell intravasation mediated by perivascular Tie2hi/VEGFAhi macrophages in the tumor microenvironment
of metastasis [57]. However, in a small Phase I clinical trial of rebastinib as a single agent in leukemia patients,
despite the systematic TIE2 inhibition measured by altered levels of Angiopoietin2 (ANG2), this resulted in only
a modest clinical benefit (NCT00827138).
The TME is rich in factors that modulate the biology of stromal and immune cells, including macrophages,
which enables their education toward a protumoral state. In liver metastases of colorectal cancer patients, one
such molecule that was recently described is the chemokine CCL5. Interestingly, this factor was supplied by
lymphocytes recruited to the invasive margin of metastatic lesions and promoted tumor growth [58]. When CCL5-
CCR5 signaling was blocked either by targeting CCR5, which is broadly expressed in the tumor tissue, or via
a neutralizing antibody for CCL5, metastatic lesion explants showed signs of necrosis and shrinkage. This effect
was entirely mediated by macrophages as clodronate liposome treatment abolished the antitumoral potency of
CCL5-CCR5 inhibition. Importantly, the depletion of macrophages alone had no antitumoral effect. Thus, only
the re-education of TAMs was capable of inducing tumor cell death, which consequently led to tumor regression
in this context. The therapeutic potential of CCL5-CCR5 blockade has been further confirmed in initial results
from a clinical trial [58]. In a small cohort of patients with advanced metastatic colorectal cancer, CCL5-CCR5
blockade was well tolerated, and associated with a decrease in tumor-promoting factors, confirming the absence of
significant side effects for the CCR5 small molecule inhibitor maraviroc [58].
Molecular mechanisms governing the education of macrophages toward protumoral phenotypes and functions
are currently only partially understood. Once the full spectrum of these molecular pathways is revealed, the
possibilities for their therapeutic targeting in cancer should inevitably follow. As a representative example, a recent
study showed that macrophages deficient for DICER, an enzyme involved in miRNA biogenesis, are resistant to
tumor-derived signals and consequently do not undergo polarization to an M2-like phenotype [59]. Macrophage-
specific deletion of DICER led to a slower growth of breast, lung and colon implanted solid tumors, where tumor
weight was decreased by twofold compared with wild-type control animals at the trial end point. Additionally,
the pulmonary metastasis load was decreased in both spontaneous and intravenously injected metastasis models
when DICER was deleted in the macrophages. Moreover, the TME populated by DICER-deficient TAMs was
characterized by activation of the IFN-γ/STAT1 signaling pathway, which rendered it more proinflammatory with
a higher abundance of infiltrating CD8+ T cells. Importantly, the depletion of these DICER-null macrophages via
a CSF-1R antibody had detrimental effects as this then accelerated tumor growth in colon and lung carcinomas.
Taken together, these results show the beneficial role of TAMs in tumor suppression if they are directed toward a
proinflammatory phenotype. Moreover, DICER deficiency in TAMs resulted in better control of tumor growth by
the immune system when stimulated either by anti-PD-1 or anti-CD40 treatments, which led to colon carcinoma
eradication in 16 of 20, and 10 of 10, treated animals respectively at the trial end point [59]. This and other
representative examples discussed above demonstrate how TAM re-education can have consequences for the entire
TME, rendering tumors more sensitive to immune checkpoint blockade.
Another promising strategy to treat cancer is via engineered oncolytic viruses that are designed to selectively kill
cancer cells without affecting the viability of stromal and immune cells within the TME [60]. A recent study explored
the therapeutic use of oncolytic viruses encoding IL-12, a proinflammatory cytokine that was previously shown to
be important for the antitumoral capabilities of myeloid cells [61]. The delivery of viral particles to glioblastomas
resulted in the expected cancer cell death, in addition to the skewing of TAMs toward a more proinflammatory
phenotype [62]. This activation of TAMs rendered the gliomas sensitive to anti-PD-1 and anti-CTLA-4 inhibitors
when used together with the virus treatment, resulting in a significant survival benefit and eradication of the gliomas
in 89% of treated animals. Importantly, tumor-bearing animals that were effectively cured with the combination
of oncolytic viruses and checkpoint inhibitors were immune to subsequent experimental implantation of glioma
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cells in the contralateral hemisphere [62]. Histological analysis of the brain did not reveal any detectable tumor cells
in either hemisphere after 9 months post-treatment. Once again, this example underscores how manipulating the
activation status of macrophages can render tumors sensitive to otherwise inefficient therapeutic interventions.
Finally, a recent report demonstrated the role of protein deacetylases in TAM education. Treatment with a small
molecule inhibitor of class IIa histone deacetylases, TMP195, resulted in stabilization of the tumor volume [63].
TMP195 treatment also resulted in an approximately threefold lower frequency of pulmonary metastasis in the
MMTV-PyMT transgenic model of breast cancer [63]. Detailed gene expression analyses revealed that TMP195
induced a switch in the activation profile of TAMs in mammary tumors, while it had no effect on CD3+ tumor-
associated lymphocytes. This alteration was caused by a simultaneous decrease in the protumoral subset of TAMs
defined as CD11blow and an increased abundance of CD11bhigh, F4/80 andMAC-2 expressing cells. Consequently,
the re-educated TAMs showed higher phagocytic capacity and induced normalization of the tumor vasculature.
Importantly, simple depletion of all TAM subsets with an anti-CSF-1 antibody did not result in any tumor regression
and it abrogated the effects of the TMP195 drug. These results again highlight that re-education of TAMs rather
than their depletion can induce more profound changes in the TME that lead to the efficient inhibition of tumor
growth and decrease in the metastases occurrence in this example, or bona fide tumor regression in other cancers.
Similar to the studies discussed above, when TAMs were re-educated by TMP195, MMTV-PyMT tumors then
became susceptible to PD-1/PD-L1 blockade, which was ineffective as monotherapy [63].
Conclusions
Together, the representative studies discussed in this perspective highlight a growing body of evidence that TAM
education not only results in a diverse array of tumor-promoting functions for these cells, but also orchestrates a
plethora of immune system–tumor interactions thereby representing a major obstacle for the efficacy of various
immunotherapies. As such, the re-education of TAMs to overcome an immunosuppressive environment presents
an attractive means of attack, as exemplified by the studies discussed herein. Particularly in cases where TAM
depletion deos not deliver a pronounced therapeutic effect, manipulation of the TME via TAM re-education can
offer a promising alternative strategy. Although TAM targeting and re-education can represent a potent approach
as a monotherapy [17], it may result in the development of resistance and tumor rebound [41], or even accelerate
tumor growth once therapy is ceased [24]. On the other hand, the antitumoral potential of TAM-targeted therapies
is greatly enhanced when combined with other immune-centered therapies such as targeting the PD-1/PD-L1 and
CTLA-4 immune checkpoints. In several preclinical tumor models, this approach was shown to unleash antitumor
immunity, leading to tumor regression and even apparent disease eradication. Thus, the potential of TAM-directed
therapies lies in combination with other treatments such as immune checkpoint inhibitors or chemotherapy, which
is expected to be broadly explored in the coming years.
Future perspective
Despite the promising results discussed here, particularly in preclinical models, many questions remain unanswered
and further studies are needed to deeply understand the complexity of TAM biology. Several studies have shown
that TAMs can be phenotypically heterogeneous within a single tumor [36,49,53], and recent reports have revealed
that ontologically distinct cells can be both similarly and differentially educated within a single TME. For example,
in brain malignancies [38,64], lung cancer [65], and in PDAC models [66], both tissue-resident and bone marrow-
derived macrophages are recruited to the developing tumor mass and further educated in situ by cancer cells, adding
multiple layers of complexity. With these new findings revealing distinct TAM progenitor pools, and different
modes of tumor-mediated education, several important and intriguing questions are raised: Does ontogeny imprint
the function of TAMs in the TME and also in response to various therapies? Should we move from general TAM
targeting to therapies directed to TAM subpopulations? If so, which subset of TAMs is more prone to be re-educated,
and which represents the most potent therapeutic target? Will TAM re-education strategies need to be adapted
for individual organs and TMEs? Another general challenge is to translate promising preclinical results into the
clinic. Macrophage-centered therapies have so far been evaluated mostly as monotherapies, with multiple preclinical
studies demonstrating the feasibility and efficacy of this approach. However, TAM-directed monotherapies have
provided limited benefit for patient health in the clinical trials reported to date [25]. Thus, clinical trials evaluating
TAM-focused therapies in rational combinations with other immunotherapeutic interventions, or other anticancer
agents, are clearly needed going forward to achieve beneficial outcomes for cancer patients. Addressing these
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Executive summary
Tumor-associated macrophages in the cancer microenvironment
• Tumors develop and progress within a complex tissue environment that collectively comprises the tumor
microenvironment (TME).
• Tumor-associated macrophages (TAMs) represent one of the most abundant nontransformed cell types present
within the TME.
• Macrophages can acquire protumoral phenotypes during the process of their education within the TME, and
their abundance and tumor-promoting phenotypes correlate with poor patient prognosis.
• Multiple strategies are being developed to target TAMs as anticancer therapies.
Strategies to deplete or re-educate TAMs
Targeting of macrophages via the CSF-1/CSF-1R pathway
• CSF-1/CSF-1R inhibition leads either to depletion or re-education of TAMs within the TME and has antitumoral
effects in several preclinical cancer models.
• CSF-1/CSF-1R inhibition can be circumvented by acquired changes in the TME. However, this can be overcome by
combining CSF-1R blockade with targeting of other TME-derived protumorigenic factors.
Targeting of macrophages via CD40
• CD40 agonists repolarize macrophages and boost antitumoral immune responses.
• Combination of different CD40 agonists with CSF-1/CSF-1R pathway inhibition amplifies antitumorigenic effects
and results in a more potent tumor regression compared with single agents across a large panel of preclinical
cancer models.
• Combination of anti-CD40 and anti-CSF-1R positively enhances the effect of anti-PD-L1 treatment.
Targeting of macrophages via PD-1 inhibition
• The therapeutic effect of PD-1/PD-L1 targeting can be mediated by PD-1+ macrophages in both
immunocompetent and immunocompromised animals.
• The beneficial effect of PD-1 can be abrogated in the absence of tumor-associated macrophages.
Targeting of macrophages via kinase inhibition
• Ablation of macrophage-supplied PI3Kγ in tumor-bearing animals suppresses tumor growth.
• PI3Kγ inhibition results in TAM repolarization and immune system activation that together delay tumor growth.
• PI3Kγ inhibition sensitizes tumors to immune checkpoint inhibitors.
• Tie2 is expressed by a subset of tumor-associated macrophages involved in metastatic dissemination.
• Tie2 inhibition decreases metastatic burden.
Targeting of macrophages via CCL5/CCR5 pathway
• Blockade of CCL5-CCR5 signaling results in macrophage activation and necrosis of metastatic lesions in a
preclinical model.
• A subsequent clinical trial supported the therapeutic potential of CCL5-CCR5 targeting.
Targeting of macrophages via DICER pathway
• DICER deletion in macrophages results in slower tumor growth and lower incidence of metastases in cancer
models.
• Depletion of DICER-deficient TAMs specifically via an anti-CSF-1R antibody accelerates tumor growth.
• DICER-deficient TAMs render the TME more proinflammatory, and enables the beneficial effect of both anti-PD-1
and anti-CD40 treatments.
Targeting of macrophages via oncolytic viruses
• Delivery of oncolytic viruses encoding IL-12 results in cancer cell death and skews TAMs toward a
proinflammatory phenotype.
• Viral treatment combined with anti-PD-1 and anti-CTLA-4 inhibitors leads to eradication of preclinical gliomas in
the majority of treated animals.
Targeting of macrophages via class IIa histone deacetylase
• Treatment with the class IIa histone deacetylase inhibitor TMP195 results in stabilization of tumor volume and a
reduced frequency of spontaneous metastases in preclinical trials.
• TMP195 acts on TAMs and induces a higher phagocytic capacity and normalization of the tumor vasculature.
• TMP195 unmasks an antitumor effect of PD-1/PD-L1 blockade in otherwise insensitive MMTV-PyMT tumors.
Conclusions
• Therapeutic targeting of macrophages is a feasible approach that can lead to antitumorigenic effects.
• TAM re-education renders tumors susceptible to otherwise inefficient immunotherapies, thus TAMs emerge as a
key orchestrator of the immune response against cancer.
different challenges should then facilitate the tailoring of TAM-targeted therapies in order to induce prolonged
antitumor efficacy across diverse cancer types.
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